Daiichi Sankyo and LYSA-LYSARC-CALYM Enter Research Collaboration for Valemetostat in Patients with Relapsed/Refractory B-Cell Lymphoma yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Rituximab Biosimilars Global Market Report 2020-30: Covid 19 Growth And Change
The Business Research Company’s Rituximab Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change
LONDON, GREATER LONDON, UK, February 8, 2021 /EINPresswire.com/
New year, new updates! Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports
The rising prevalence of non-Hodgkin’s lymphoma (NHL) is predicted to contribute to the growth of the rituximab biosimilars market. Non-Hodgkin’s lymphoma is a cancer that starts in white blood cells (lymphocytes) that are part of the body’s immune system. In 2018, rituximab-abbs was approved as the first rituximab biosimilars for the treatment of patients with B-cell NHL and adult patients with CD20-positive. According to the National Library of Medicine’s statistics, non-Hodgkin lymphoma was ranked as the 5th to 9th
MedCity News
Bristol Myers lymphoma therapy acquired in Celgene deal wins FDA nod
After some setbacks and delays, the FDA approved Bristol Myers Squibb’s Breyanzi for certain lymphomas. It’s the fourth CAR T treatment to win the regulatory nod and the first under a new regenerative medicine designation.
Shares1
A Bristol Myers Squibb cancer immunotherapy that the pharmaceutical giant obtained via its Celgene acquisition was awarded FDA approval Friday, adding one more of this type of personalized medicine as a treatment option for certain forms of lymphoma.
The FDA approved the therapy, lisocabtagene maraleucel, as a treatment for adults who have certain types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL), whose cancer has not responded to or has relapsed after at least two other types of treatment. New York-based BMS will market the drug under the name Breyanzi.
100+
pipeline drugs in the Diffuse Large B Cell Lymphoma pipeline landscape. It comprises DLBCL pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Diffuse Large B Cell Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights the inactive DLBCL pipeline products.
Some of the significant
Highlights Several prominent companies such as ADC Therapeutics, BeiGene, Nordic Nanovector, bluebird bio, Celgene, GlaxoSmithKline, AbbVie, Roche and many others are working to assess challenges and seek opportunities that could influence Diffuse Large B-cell Lymphoma R&D. The DLBCL pipeline therapies are focused on novel approaches for the treatment.
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, announced that the National Medical Products Administration (NMPA) accepted its New Drug Application (NDA) for ATG-010 (Selinexor, XPOVIO®), a first-in-class oral selective inhibitor of nuclear export (SINE) compound, for the treatment of patients with relapsed/refractory multiple myeloma (rrMM). This is the fifth NDA for ATG-010 submitted by Antengene, after the four NDAs recently submitted in Australia, South Korea, Singapore and Hong Kong in the Asia Pacific region, and also the first NDA of SINE compounds in mainland China, a step closer to providing a novel option to Chinese patients diagnosed with hematological malignancies.